尼妥珠单抗联合顺铂及放疗对中晚期宫颈癌患者血清肿瘤标志物及病灶癌细胞增殖的影响

Effect of Nituzumab Combined with Cisplatin and Radiotherapy on Serum Tumor Markers and Tumor Cell Proliferation in Patients with Advanced Cervical Cancer

目的评估尼妥珠单抗联合顺铂及放疗对中晚期宫颈癌患者血清肿瘤标志物及病灶癌细胞增殖的影响。方法选取2017年1月-2020年1月我院收治的54例中晚期宫颈癌患者为研究对象,采用随机数字表法分为对照组和观察组,各27例。对照组采用顺铂联合放疗进行治疗,观察组在对照组基础上联合尼妥珠单抗治疗,比较两组近期治疗疗效、血清肿瘤标志物表达、抗增殖基因mRNA表达、局部复发率、生存率及不良反应发生情况。结果观察组近期总有效率为96.29%,与对照组的92.59%比较,差异无统计学意义(P>0.05)。治疗后,观察组血清肿瘤标志物CA125、SCC、CA19-9水平低于对照组,抗增殖基因PTEN、FHIT、STC1 mRNA表达高于对照组(P<0.05)。观察组随访1年局部复发率低于对照组,6个月、1年生存率高于对照组(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论尼妥珠单抗联合顺铂及放疗治疗中晚期宫颈癌近期疗效确切,可降低血清肿瘤标志物水平,提高抗增殖基因mRNA表达,降低局部复发率,延长患者生存期,且不会增加临床不良反应。

Objective To evaluate the effect of nituzumab combined with cisplatin and radiotherapy on serum tumor markers and tumor cell proliferation in patients with advanced cervical cancer.Methods A total of 54 patients with advanced cervical cancer admitted to our hospital from January 2017 to January 2020 were selected as the research objects.They were divided into control group and observation group by random number table method,27 cases in each group.The control group was treated with cisplatin combined with radiotherapy,and the observation group was treated with nimotuzumab on the basis of the control group.The short-term therapeutic efficacy,serum tumor marker expression,anti-proliferative gene mRNA expression,local recurrence rate,survival rate and adverse reactions were compared between the two groups.Results The short-term total effective rate was 96.29%in the observation group,which was compared with 92.59%of the control group,with no significant difference(P>0.05).After treatment,the levels of serum tumor markers CA125,SCC and CA19-9 in the observation group were lower than those in the control group,and the expression of anti-proliferative genes PTEN,FHIT and STC1 mRNA in the observation group were higher than those in the control group(P<0.05).The local recurrence rate was lower than that in the control group,and the 6-month and 1-year survival rates were higher than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Nimotuzumab combined with cisplatin and radiotherapy is effective in the treatment of advanced cervical cancer,which can reduce the level of serum tumor markers,improve the expression of antiproliferative gene mRNA,reduce local recurrence rate,increase the survival time of patients,and do not increase clinical adverse reactions.